CLU and acute kidney injury: Despite promise, a lack of specificity for AKI means KIM-1 and NAGL may be better suited to a biomarker panel (Medić et al. 2016), reflected by their inclusion in an FDA qualified panel of six urine creatinine-normalized biomarkers also containing clusterin and cystain C to monitor kidney toxicity during early phase clinical trials (Sandelius et al. 2020).